Notification of inability to timely file Form 10-Q or 10-QSB



>

















SEC File Number:

0-54296







CUSIP Number:

05463J 107







UNITED STATES




SECURITIES AND EXCHANGE COMMISSION




Washington, D.C.  20549






FORM 12b-25






NOTIFICATION OF LATE FILING





(Check one):





[  ] Form 10-K    [  ] Form 20-F    [  ] Form 11-K

[X] Form 10-Q

[  ] Form 10-D    [  ] Form N-SAR







For Period Ended:

March 31, 2020






[   ]



Transition Report on Form 10-K




[   ]



Transition Report on Form 20-F




[   ]



Transition Report on Form 11-K




[   ]



Transition Report on Form 10-Q




[   ]



Transition Report on Form N-SAR





For the Transition Period Ended: _______________






Read Instruction (on back page) Before Preparing Form.  Please Print or Type.



Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.





If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:







PART I  -  REGISTRANT INFORMATION























Full Name of Registrant:





Axim Biotechnologies, Inc.




Former Name if Applicable:







Address of Principal Executive Office (Street and Number):






6191 Cornerstone Court, E., Suite 114





City, State and Zip Code:





San Diego, CA 92121







PART II  -  RULES 12b-25(b) AND (c)





If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.  (Check box if appropriate)


























[

X

]




(a)




The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;






(b)




The subject annual report, semi-annual report, transition report on Forms 10-K, 20-F, 11-K, Form N-SAR, or Form N-CSR or portion thereof, will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and






(c)




The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.











PART III  -  NARRATIVE






S

tate below in reasonable detail the reasons why Forms 10-K, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report portion thereof, could not be filed within the prescribed time period.








There will be a delay in filing the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, because the Company needs additional time to finish the Report and to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T.  Exhibit 101 to the Form 10-Q provides the financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language).






PART IV  -  OTHER INFORMATION






(1)



Name and telephone number of person to contact in regard to this notification:


















John W. Huemoeller II








(212) 332-1677




(Name)







(Area Code) (Telephone number)







(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter) period that the registrant was required to file such reports) been filed?  If answer is no, identify report(s):    [

X

]  Yes [   ]  No






(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof:  [   ]  Yes [

X

]  No





If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.














AXIM Biotechnologies, Inc.




(Name of Registrant as Specified in Charter)






has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

















Date: June 29, 2020








/s/



John W. Huemoeller II












John W. Huemoeller II President








INSTRUCTION:  The form may be signed by an executive officer of the registrant or by any other duly authorized representative.  The name and title of the person signing the form shall be typed or printed beneath the signature.  If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.






The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Axim Biotechnologies, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

AXIM® Biotechnologies Issues Update Letter to Shareholders - Oct. 28, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19) - Oct. 6, 2020
AXIM® Biotechnologies Files Patent for Virus Binding Recombinant Protein for SARS-CoV-2 (COVID-19) and Begins Manufacturing - Sept. 30, 2020

Auto Refresh

Feedback